Stem cell therapy for cardiac disease is an exciting but highly controversial research area.
Strategies such as cell transplantation and reprogramming have demonstrated both …

Despite refinements of medical and surgical therapies, heart failure remains a fatal disease.
Myocardial infarction is the most common cause of heart failure, and only palliative …

Despite significant therapeutic advances, the prognosis of patients with heart failure (HF)
remains poor, and current therapeutic approaches are palliative in the sense that they do not …

Heart failure carries a poor prognosis with few treatment options. While myocardial stem cell
therapeutic trials have traditionally relied on intracoronary infusion or intramyocardial …

Cardiovascular disease (CVD) can be separated into two broad etiological categories,
based on the presence or absence of ischemia as a causative factor. In both ischemic and …

Heart failure remains a major cause of death and disability, requiring rapid development of
new therapies. Bone marrow-derived mesenchymal stem cell (MSC)-based therapy is an …

Background c-kit-positive, lineage-negative cardiac stem cells (CSCs) improve post-
infarction left ventricular (LV) dysfunction when administered to animals. We undertook a …

Given the rising prevalence of cardiovascular disease worldwide and the limited therapeutic
options for severe heart failure, novel technologies that harness the regenerative capacity of …

Background—This study evaluated the hypothesis that transendocardial injections of
autologous mononuclear bone marrow cells in patients with end-stage ischemic heart …

Heart failure is the number one killer worldwide with~ 50% of patients dying within 5 years of
prognosis. The discovery of stem cells, which are capable of repairing the damaged portion …